Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1974 Mar;9(3):519–523. doi: 10.1128/iai.9.3.519-523.1974

Attenuation of Rhinovirus Type 15: Relation of Illness to Plaque Size

R Gordon Douglas Jr 1,2, Robert B Couch 1,2, Barbara D Baxter 1,2, Michael Gough 1,2,1
PMCID: PMC414837  PMID: 4361354

Abstract

Rhinovirus type 15 passaged three times in WI-38 cells produced illness in only one of 35 volunteers, but infection resulted in formation of significant quantities of antibodies in the serums of 100%, and in nasal secretions of 89%, of infected volunteers. The inoculum contained large- (60%) and small- (40%) plaque variants. “Purified” large- and small-plaque inocula were prepared, and each was administered to 20 volunteers. There was a significant association of illness with the small-plaque inocula (P < 0.01) but the incidence of infection, quantitative virus shedding patterns, and mean serum and nasal secretory antibodies were not significantly different between the two groups. These findings suggest that plaque size may be an in vitro marker of attenuation of illness production by rhinoviruses.

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CATE T. R., COUCH R. B., JOHNSON K. M. STUDIES WITH RHINOVIRUSES IN VOLUNTEERS: PRODUCTION OF ILLNESS, EFFECT OF NATURALLLY ACQUIRED ANTIBODY, AND DEMONSTRATION OF A PROTECTIVE EFFECT NOT ASSOCIATED WITH SERUM ANTIBODY. J Clin Invest. 1964 Jan;43:56–67. doi: 10.1172/JCI104894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cate T. R., Rossen R. D., Douglas R. G., Jr, Butler W. T., Couch R. B. The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol. 1966 Sep;84(2):352–363. doi: 10.1093/oxfordjournals.aje.a120648. [DOI] [PubMed] [Google Scholar]
  3. Couch R. B., Douglas R. G., Jr, Fedson D. S., Kasel J. A. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis. 1971 Nov;124(5):473–480. doi: 10.1093/infdis/124.5.473. [DOI] [PubMed] [Google Scholar]
  4. Douglas R. G., Jr, Cate T. R., Gerone P. J., Couch R. B. Quantitative rhinovirus shedding patterns in volunteers. Am Rev Respir Dis. 1966 Aug;94(2):159–167. doi: 10.1164/arrd.1966.94.2.159. [DOI] [PubMed] [Google Scholar]
  5. Douglas R. G., Jr, Couch R. B. Attenuation of rhinovirus type 15 for humans. Nature. 1969 Jul 12;223(5202):213–214. doi: 10.1038/223213b0. [DOI] [PubMed] [Google Scholar]
  6. Douglas R. G., Jr, Couch R. B. Parenteral inactivated rhinovirus vaccine: minimal protective effect. Proc Soc Exp Biol Med. 1972 Mar;139(3):899–902. doi: 10.3181/00379727-139-36262. [DOI] [PubMed] [Google Scholar]
  7. Fiala M., Kenny G. E. Enhancement of rhinovirus plaque formation in human heteroploid cell cultures by magnesium and calcium. J Bacteriol. 1966 Dec;92(6):1710–1715. doi: 10.1128/jb.92.6.1710-1715.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. KNIGHT V. THE USE OF VOLUNTEERS IN MEDICAL VIROLOGY. Prog Med Virol. 1964;6:1–26. [PubMed] [Google Scholar]
  9. Perkins J. C., Tucker D. N., Knope H. L., Wenzel R. P., Hornick R. B., Kapikian A. Z., Chanock R. M. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am J Epidemiol. 1969 Oct;90(4):319–326. doi: 10.1093/oxfordjournals.aje.a121076. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES